Wellbutrin and Bupropion: Understanding This Unique Antidepressant and Smoking Cessation Agent

Bupropion, sold under brand names including Wellbutrin and Zyban, occupies a distinctive position among antidepressant medications because its mechanism and side effect profile differ substantially from the dominant SSRIs and SNRIs in the market. It inhibits reuptake of dopamine and norepinephrine rather than serotonin, and this mechanistic difference shapes both its therapeutic advantages and its side effect profile compared to serotonergic antidepressants. Bupropion is FDA-approved for major depressive disorder, seasonal affective disorder, and smoking cessation. Its application for smoking cessation under the brand name Zyban uses identical pharmacology to the antidepressant applications and reflects the discovery that dopaminergic and noradrenergic activity appears to reduce nicotine craving and withdrawal symptoms. Both applications are supported by substantial clinical trial evidence. One of the most clinically significant attributes of bupropion compared to serotonergic antidepressants is its absence of sexual dysfunction effects. SSRIs produce sexual dysfunction including decreased libido and delayed orgasm in a substantial proportion of patients, and this side effect is a common reason for antidepressant switching or discontinuation. Bupropion does not inhibit serotonin reuptake, and therefore does not produce the serotonergic mechanism of sexual dysfunction. Patients who have experienced intolerable sexual side effects on SSRIs are frequently offered bupropion as an alternative or combination addition. Weight effects also differ between bupropion and serotonergic antidepressants. SSRIs and SNRIs are associated with weight gain in a significant proportion of patients over long-term use. Bupropion tends to be weight-neutral or associated with modest weight loss in clinical studies, making it a preferred option for patients who are concerned about weight gain from antidepressant therapy. Seizure risk is a contraindication-level concern with bupropion. The medication lowers seizure threshold in a dose-dependent manner, and this risk is particularly elevated in patients with eating disorders involving purging, a history of head trauma, or high alcohol use. Patients with any history of seizure disorder are generally not candidates for bupropion. Bupropion has a stimulating rather than sedating profile, which can benefit patients with depression characterized by fatigue, low motivation, and hypersomnia, but may worsen insomnia or anxiety in patients with significant anxiety comorbidity. For patients exploring bupropion as a depression or smoking cessation treatment, reviewing information about wellbutrin-bupropion for depression and smoking cessation provides a useful clinical overview. For context on how bupropion compares to SSRIs and other antidepressants in the full treatment landscape, antidepressant medication category guides and patient resources offers helpful comparative information.